APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PCSK9 Antagonists

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global PCSK9 Antagonists Industry Growth and Trends Forecast to 2032

Report ID 174022670128 December 2025105 pages

Choose your research edition.

Industry ResearchPCSK9 Antagonists Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal PCSK9 Antagonists Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal PCSK9 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PCSK9 Antagonists Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PCSK9 Antagonists Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global PCSK9 Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PCSK9 Antagonists include Amgen, Merck, Novartis, Regeneron Pharmaceuticals, Sanofi, Hasten Biopharmaceutical, Jiangsu Hengrui Pharmaceuticals, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global PCSK9 Antagonists market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The PCSK9 Antagonists market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PCSK9 Antagonists market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PCSK9 Antagonists.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global PCSK9 Antagonists market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

PCSK9 Antagonists Market by Company

Amgen

Merck

Novartis

Regeneron Pharmaceuticals

Sanofi

Hasten Biopharmaceutical

Jiangsu Hengrui Pharmaceuticals

Junshi Biosciences

Akeso

Innovent Biologics

Salubris Pharmaceuticals

PCSK9 Antagonists Segment by Type

Monoclonal Antibody

siRNA

Other

PCSK9 Antagonists Segment by Application

Atherosclerotic Cardiovascular Disease

Hypercholesterolemia

Others

PCSK9 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PCSK9 Antagonists manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of PCSK9 Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Monoclonal Antibody Table 2. Major Company of siRNA Table 3. Major Company of Other Table 4. Global PCSK9 Antagonists Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global PCSK9 Antagonists Sales by Type (2021-2026) & (K Units) Table 6. Global PCSK9 Antagonists Sales Market Share in Volume by Type (2021-2026) Table 7. Global PCSK9 Antagonists Sales by Type (2021-2026) & (US$ Million) Table 8. Global PCSK9 Antagonists Sales Market Share in Value by Type (2021-2026) Table 9. Global PCSK9 Antagonists Price by Type (2021-2026) & (US$/Unit) Table 10. Global PCSK9 Antagonists Sales by Type (2027-2032) & (K Units) Table 11. Global PCSK9 Antagonists Sales Market Share in Volume by Type (2027-2032) Table 12. Global PCSK9 Antagonists Sales by Type (2027-2032) & (US$ Million) Table 13. Global PCSK9 Antagonists Sales Market Share in Value by Type (2027-2032) Table 14. Global PCSK9 Antagonists Price by Type (2027-2032) & (US$/Unit) Table 15. North America PCSK9 Antagonists Sales by Type (2021-2026) & (K Units) Table 16. North America PCSK9 Antagonists Sales by Type (2021-2026) & (US$ Million) Table 17. Europe PCSK9 Antagonists Sales by Type (2021-2026) & (K Units) Table 18. Europe PCSK9 Antagonists Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific PCSK9 Antagonists Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific PCSK9 Antagonists Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America PCSK9 Antagonists Sales by Type (2021-2026) & (K Units) Table 22. Latin America PCSK9 Antagonists Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa PCSK9 Antagonists Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa PCSK9 Antagonists Sales by Type (2021-2026) & (US$ Million) Table 25. PCSK9 Antagonists Industry Trends Table 26. PCSK9 Antagonists Industry Drivers Table 27. PCSK9 Antagonists Industry Opportunities and Challenges Table 28. PCSK9 Antagonists Industry Restraints Table 29. Global PCSK9 Antagonists Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global PCSK9 Antagonists Revenue Market Share by Company (2021-2026) Table 31. Global PCSK9 Antagonists Sales by Company (2021-2026) & (K Units) Table 32. Global PCSK9 Antagonists Sales Share by Company (2021-2026) Table 33. Global PCSK9 Antagonists Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global PCSK9 Antagonists Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global PCSK9 Antagonists Major Company Production Sites and Headquarters Table 36. Global PCSK9 Antagonists Company, Product Type & Application Table 37. Global PCSK9 Antagonists Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global PCSK9 Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global PCSK9 Antagonists Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global PCSK9 Antagonists Sales by Region (2021-2026) & (K Units) Table 42. Global PCSK9 Antagonists Sales Market Share in Volume by Region (2021-2026) Table 43. Global PCSK9 Antagonists Sales by Region (2021-2026) & (US$ Million) Table 44. Global PCSK9 Antagonists Sales Market Share in Value by Region (2021-2026) Table 45. Global PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global PCSK9 Antagonists Sales by Region (2027-2032) & (K Units) Table 47. Global PCSK9 Antagonists Sales Market Share in Volume by Region (2027-2032) Table 48. Global PCSK9 Antagonists Sales by Region (2027-2032) & (US$ Million) Table 49. Global PCSK9 Antagonists Sales Market Share in Value by Region (2027-2032) Table 50. Global PCSK9 Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global PCSK9 Antagonists Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global PCSK9 Antagonists Sales by Application (2021-2026) & (K Units) Table 53. Global PCSK9 Antagonists Sales Market Share in Volume by Application (2021-2026) Table 54. Global PCSK9 Antagonists Sales by Application (2021-2026) & (US$ Million) Table 55. Global PCSK9 Antagonists Sales Market Share in Value by Application (2021-2026) Table 56. Global PCSK9 Antagonists Price by Application (2021-2026) & (US$/Unit) Table 57. Global PCSK9 Antagonists Sales by Application (2027-2032) & (K Units) Table 58. Global PCSK9 Antagonists Sales Market Share in Volume by Application (2027-2032) Table 59. Global PCSK9 Antagonists Sales by Application (2027-2032) & (US$ Million) Table 60. Global PCSK9 Antagonists Sales Market Share in Value by Application (2027-2032) Table 61. Global PCSK9 Antagonists Price by Application (2027-2032) & (US$/Unit) Table 62. North America PCSK9 Antagonists Sales by Application (2021-2026) & (K Units) Table 63. North America PCSK9 Antagonists Sales by Application (2021-2026) & (US$ Million) Table 64. Europe PCSK9 Antagonists Sales by Application (2021-2026) & (K Units) Table 65. Europe PCSK9 Antagonists Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific PCSK9 Antagonists Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific PCSK9 Antagonists Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America PCSK9 Antagonists Sales by Application (2021-2026) & (K Units) Table 69. Latin America PCSK9 Antagonists Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa PCSK9 Antagonists Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa PCSK9 Antagonists Sales by Application (2021-2026) & (US$ Million) Table 72. Amgen Company Information Table 73. Amgen Business Overview Table 74. Amgen PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Amgen PCSK9 Antagonists Product Portfolio Table 76. Amgen Recent Development Table 77. Merck Company Information Table 78. Merck Business Overview Table 79. Merck PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Merck PCSK9 Antagonists Product Portfolio Table 81. Merck Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Novartis PCSK9 Antagonists Product Portfolio Table 86. Novartis Recent Development Table 87. Regeneron Pharmaceuticals Company Information Table 88. Regeneron Pharmaceuticals Business Overview Table 89. Regeneron Pharmaceuticals PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Regeneron Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 91. Regeneron Pharmaceuticals Recent Development Table 92. Sanofi Company Information Table 93. Sanofi Business Overview Table 94. Sanofi PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Sanofi PCSK9 Antagonists Product Portfolio Table 96. Sanofi Recent Development Table 97. Hasten Biopharmaceutical Company Information Table 98. Hasten Biopharmaceutical Business Overview Table 99. Hasten Biopharmaceutical PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Hasten Biopharmaceutical PCSK9 Antagonists Product Portfolio Table 101. Hasten Biopharmaceutical Recent Development Table 102. Jiangsu Hengrui Pharmaceuticals Company Information Table 103. Jiangsu Hengrui Pharmaceuticals Business Overview Table 104. Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 106. Jiangsu Hengrui Pharmaceuticals Recent Development Table 107. Junshi Biosciences Company Information Table 108. Junshi Biosciences Business Overview Table 109. Junshi Biosciences PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Junshi Biosciences PCSK9 Antagonists Product Portfolio Table 111. Junshi Biosciences Recent Development Table 112. Akeso Company Information Table 113. Akeso Business Overview Table 114. Akeso PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Akeso PCSK9 Antagonists Product Portfolio Table 116. Akeso Recent Development Table 117. Innovent Biologics Company Information Table 118. Innovent Biologics Business Overview Table 119. Innovent Biologics PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Innovent Biologics PCSK9 Antagonists Product Portfolio Table 121. Innovent Biologics Recent Development Table 122. Salubris Pharmaceuticals Company Information Table 123. Salubris Pharmaceuticals Business Overview Table 124. Salubris Pharmaceuticals PCSK9 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Salubris Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 126. Salubris Pharmaceuticals Recent Development Table 127. North America PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. North America PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 129. North America PCSK9 Antagonists Sales Market Share by Country (2021-2026) Table 130. North America PCSK9 Antagonists Sales Forecast by Country (2027-2032) & (K Units) Table 131. North America PCSK9 Antagonists Sales Market Share Forecast by Country (2027-2032) Table 132. North America PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. North America PCSK9 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 134. North America PCSK9 Antagonists Market Share by Country (2021-2026) Table 135. North America PCSK9 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. North America PCSK9 Antagonists Market Share Forecast by Country (2027-2032) Table 137. Europe PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Europe PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 139. Europe PCSK9 Antagonists Sales Market Share by Country (2021-2026) Table 140. Europe PCSK9 Antagonists Sales Forecast by Country (2027-2032) & (K Units) Table 141. Europe PCSK9 Antagonists Sales Market Share Forecast by Country (2027-2032) Table 142. Europe PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Europe PCSK9 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 144. Europe PCSK9 Antagonists Market Share by Country (2021-2026) Table 145. Europe PCSK9 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Europe PCSK9 Antagonists Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 149. Asia-Pacific PCSK9 Antagonists Sales Market Share by Country (2021-2026) Table 150. Asia-Pacific PCSK9 Antagonists Sales Forecast by Country (2027-2032) & (K Units) Table 151. Asia-Pacific PCSK9 Antagonists Sales Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific PCSK9 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 154. Asia-Pacific PCSK9 Antagonists Market Share by Country (2021-2026) Table 155. Asia-Pacific PCSK9 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Asia-Pacific PCSK9 Antagonists Market Share Forecast by Country (2027-2032) Table 157. Latin America PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 158. Latin America PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 159. Latin America PCSK9 Antagonists Sales Market Share by Country (2021-2026) Table 160. Latin America PCSK9 Antagonists Sales Forecast by Country (2027-2032) & (K Units) Table 161. Latin America PCSK9 Antagonists Sales Market Share Forecast by Country (2027-2032) Table 162. Latin America PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Latin America PCSK9 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 164. Latin America PCSK9 Antagonists Market Share by Country (2021-2026) Table 165. Latin America PCSK9 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Latin America PCSK9 Antagonists Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 169. Middle East and Africa PCSK9 Antagonists Sales Market Share by Country (2021-2026) Table 170. Middle East and Africa PCSK9 Antagonists Sales Forecast by Country (2027-2032) & (K Units) Table 171. Middle East and Africa PCSK9 Antagonists Sales Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa PCSK9 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 174. Middle East and Africa PCSK9 Antagonists Market Share by Country (2021-2026) Table 175. Middle East and Africa PCSK9 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Middle East and Africa PCSK9 Antagonists Market Share Forecast by Country (2027-2032) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. PCSK9 Antagonists Distributors List Table 180. PCSK9 Antagonists Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. PCSK9 Antagonists Image Figure 2. Global PCSK9 Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PCSK9 Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global PCSK9 Antagonists Sales (2021-2032) & (K Units) Figure 5. Monoclonal Antibody Image Figure 6. Global Monoclonal Antibody Sales YoY Growth (2021-2032) & (K Units) Figure 7. siRNA Image Figure 8. Global siRNA Sales YoY Growth (2021-2032) & (K Units) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global PCSK9 Antagonists Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global PCSK9 Antagonists Market Share by Type 2025 VS 2032 Figure 13. North America PCSK9 Antagonists Sales Market Share in Volume by Type in 2025 Figure 14. North America PCSK9 Antagonists Sales Market Share in Value by Type in 2025 Figure 15. Europe PCSK9 Antagonists Sales Market Share in Volume by Type in 2025 Figure 16. Europe PCSK9 Antagonists Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific PCSK9 Antagonists Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific PCSK9 Antagonists Sales Market Share in Value by Type in 2025 Figure 19. Latin America PCSK9 Antagonists Sales Market Share in Volume by Type in 2025 Figure 20. Latin America PCSK9 Antagonists Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa PCSK9 Antagonists Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa PCSK9 Antagonists Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 PCSK9 Antagonists Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Atherosclerotic Cardiovascular Disease Image Figure 26. Global Atherosclerotic Cardiovascular Disease Sales YoY Growth (2021-2032) & (K Units) Figure 27. Hypercholesterolemia Image Figure 28. Global Hypercholesterolemia Sales YoY Growth (2021-2032) & (K Units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global PCSK9 Antagonists Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global PCSK9 Antagonists Market Share by Application 2025 VS 2032 Figure 33. North America PCSK9 Antagonists Sales Market Share in Volume by Application in 2025 Figure 34. North America PCSK9 Antagonists Sales Market Share in Value by Application in 2025 Figure 35. Europe PCSK9 Antagonists Sales Market Share in Volume by Application in 2025 Figure 36. Europe PCSK9 Antagonists Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific PCSK9 Antagonists Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific PCSK9 Antagonists Sales Market Share in Value by Application in 2025 Figure 39. Latin America PCSK9 Antagonists Sales Market Share in Volume by Application in 2025 Figure 40. Latin America PCSK9 Antagonists Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa PCSK9 Antagonists Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa PCSK9 Antagonists Sales Market Share in Value by Application in 2025 Figure 43. North America PCSK9 Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America PCSK9 Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America PCSK9 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe PCSK9 Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe PCSK9 Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe PCSK9 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific PCSK9 Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific PCSK9 Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific PCSK9 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America PCSK9 Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America PCSK9 Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America PCSK9 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa PCSK9 Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa PCSK9 Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa PCSK9 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. PCSK9 Antagonists Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. PCSK9 Antagonists Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • siRNA
  • Other
Applications
  • Atherosclerotic Cardiovascular Disease
  • Hypercholesterolemia
  • Others
Companies covered
  • Amgen
  • Merck
  • Novartis
  • Regeneron Pharmaceuticals
  • Sanofi
  • Hasten Biopharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Junshi Biosciences
  • Akeso
  • Innovent Biologics
  • Salubris Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PCSK9 Antagonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global PCSK9 Antagonists Sales Estimates and Forecasts (2021-2032)
  5. 1.3 PCSK9 Antagonists Market by Type
  6. 1.3.1 Monoclonal Antibody
  7. 1.3.2 siRNA
  8. 1.3.3 Other
  9. 1.4 Global PCSK9 Antagonists Market Size by Type
  10. 1.4.1 Global PCSK9 Antagonists Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global PCSK9 Antagonists Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global PCSK9 Antagonists Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America PCSK9 Antagonists Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe PCSK9 Antagonists Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific PCSK9 Antagonists Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America PCSK9 Antagonists Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa PCSK9 Antagonists Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 PCSK9 Antagonists Industry Trends
  2. 2.2 PCSK9 Antagonists Industry Drivers
  3. 2.3 PCSK9 Antagonists Industry Opportunities and Challenges
  4. 2.4 PCSK9 Antagonists Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by PCSK9 Antagonists Revenue (2021-2026)
  2. 3.2 Global Top Players by PCSK9 Antagonists Sales (2021-2026)
  3. 3.3 Global Top Players by PCSK9 Antagonists Price (2021-2026)
  4. 3.4 Global PCSK9 Antagonists Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PCSK9 Antagonists Major Company Production Sites & Headquarters
  6. 3.6 Global PCSK9 Antagonists Company, Product Type & Application
  7. 3.7 Global PCSK9 Antagonists Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PCSK9 Antagonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PCSK9 Antagonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PCSK9 Antagonists Tier 1, Tier 2, and Tier 3
4 PCSK9 Antagonists Regional Status and Outlook
  1. 4.1 Global PCSK9 Antagonists Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global PCSK9 Antagonists Historic Market Size by Region
  3. 4.2.1 Global PCSK9 Antagonists Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global PCSK9 Antagonists Sales in Value by Region (2021-2026)
  5. 4.2.3 Global PCSK9 Antagonists Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global PCSK9 Antagonists Forecasted Market Size by Region
  7. 4.3.1 Global PCSK9 Antagonists Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global PCSK9 Antagonists Sales in Value by Region (2027-2032)
  9. 4.3.3 Global PCSK9 Antagonists Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 PCSK9 Antagonists by Application
  1. 5.1 PCSK9 Antagonists Market by Application
  2. 5.1.1 Atherosclerotic Cardiovascular Disease
  3. 5.1.2 Hypercholesterolemia
  4. 5.1.3 Others
  5. 5.2 Global PCSK9 Antagonists Market Size by Application
  6. 5.2.1 Global PCSK9 Antagonists Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global PCSK9 Antagonists Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global PCSK9 Antagonists Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America PCSK9 Antagonists Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe PCSK9 Antagonists Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific PCSK9 Antagonists Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America PCSK9 Antagonists Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa PCSK9 Antagonists Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Amgen
  2. 6.1.1 Amgen Company Information
  3. 6.1.2 Amgen Business Overview
  4. 6.1.3 Amgen PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Amgen PCSK9 Antagonists Product Portfolio
  6. 6.1.5 Amgen Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck PCSK9 Antagonists Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis PCSK9 Antagonists Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Regeneron Pharmaceuticals
  20. 6.4.1 Regeneron Pharmaceuticals Company Information
  21. 6.4.2 Regeneron Pharmaceuticals Business Overview
  22. 6.4.3 Regeneron Pharmaceuticals PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Regeneron Pharmaceuticals PCSK9 Antagonists Product Portfolio
  24. 6.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi PCSK9 Antagonists Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Hasten Biopharmaceutical
  32. 6.6.1 Hasten Biopharmaceutical Company Information
  33. 6.6.2 Hasten Biopharmaceutical Business Overview
  34. 6.6.3 Hasten Biopharmaceutical PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Hasten Biopharmaceutical PCSK9 Antagonists Product Portfolio
  36. 6.6.5 Hasten Biopharmaceutical Recent Developments
  37. 6.7 Jiangsu Hengrui Pharmaceuticals
  38. 6.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
  39. 6.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  40. 6.7.3 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Product Portfolio
  42. 6.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  43. 6.8 Junshi Biosciences
  44. 6.8.1 Junshi Biosciences Company Information
  45. 6.8.2 Junshi Biosciences Business Overview
  46. 6.8.3 Junshi Biosciences PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Junshi Biosciences PCSK9 Antagonists Product Portfolio
  48. 6.8.5 Junshi Biosciences Recent Developments
  49. 6.9 Akeso
  50. 6.9.1 Akeso Company Information
  51. 6.9.2 Akeso Business Overview
  52. 6.9.3 Akeso PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Akeso PCSK9 Antagonists Product Portfolio
  54. 6.9.5 Akeso Recent Developments
  55. 6.10 Innovent Biologics
  56. 6.10.1 Innovent Biologics Company Information
  57. 6.10.2 Innovent Biologics Business Overview
  58. 6.10.3 Innovent Biologics PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Innovent Biologics PCSK9 Antagonists Product Portfolio
  60. 6.10.5 Innovent Biologics Recent Developments
  61. 6.11 Salubris Pharmaceuticals
  62. 6.11.1 Salubris Pharmaceuticals Company Information
  63. 6.11.2 Salubris Pharmaceuticals Business Overview
  64. 6.11.3 Salubris Pharmaceuticals PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Salubris Pharmaceuticals PCSK9 Antagonists Product Portfolio
  66. 6.11.5 Salubris Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America PCSK9 Antagonists Sales by Country
  2. 7.1.1 North America PCSK9 Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America PCSK9 Antagonists Sales by Country (2021-2026)
  4. 7.1.3 North America PCSK9 Antagonists Sales Forecast by Country (2027-2032)
  5. 7.2 North America PCSK9 Antagonists Market Size by Country
  6. 7.2.1 North America PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America PCSK9 Antagonists Market Size by Country (2021-2026)
  8. 7.2.3 North America PCSK9 Antagonists Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe PCSK9 Antagonists Sales by Country
  2. 8.1.1 Europe PCSK9 Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe PCSK9 Antagonists Sales by Country (2021-2026)
  4. 8.1.3 Europe PCSK9 Antagonists Sales Forecast by Country (2027-2032)
  5. 8.2 Europe PCSK9 Antagonists Market Size by Country
  6. 8.2.1 Europe PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe PCSK9 Antagonists Market Size by Country (2021-2026)
  8. 8.2.3 Europe PCSK9 Antagonists Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific PCSK9 Antagonists Sales by Country
  2. 9.1.1 Asia-Pacific PCSK9 Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific PCSK9 Antagonists Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific PCSK9 Antagonists Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific PCSK9 Antagonists Market Size by Country
  6. 9.2.1 Asia-Pacific PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific PCSK9 Antagonists Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific PCSK9 Antagonists Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America PCSK9 Antagonists Sales by Country
  2. 10.1.1 South America PCSK9 Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America PCSK9 Antagonists Sales by Country (2021-2026)
  4. 10.1.3 South America PCSK9 Antagonists Sales Forecast by Country (2027-2032)
  5. 10.2 South America PCSK9 Antagonists Market Size by Country
  6. 10.2.1 South America PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America PCSK9 Antagonists Market Size by Country (2021-2026)
  8. 10.2.3 South America PCSK9 Antagonists Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa PCSK9 Antagonists Sales by Country
  2. 11.1.1 Middle East and Africa PCSK9 Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa PCSK9 Antagonists Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa PCSK9 Antagonists Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa PCSK9 Antagonists Market Size by Country
  6. 11.2.1 Middle East and Africa PCSK9 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa PCSK9 Antagonists Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa PCSK9 Antagonists Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 PCSK9 Antagonists Value Chain Analysis
  2. 12.1.1 PCSK9 Antagonists Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 PCSK9 Antagonists Production Mode & Process
  7. 12.2 PCSK9 Antagonists Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 PCSK9 Antagonists Distributors
  10. 12.2.3 PCSK9 Antagonists Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst